Myriad Genetics Files 8-K on Financials

TL;DR

MYGN filed an 8-K on Jan 15, 2025, detailing financial results. Check it out.

AI Summary

Myriad Genetics, Inc. filed an 8-K on January 15, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Salt Lake City, Utah.

Why It Matters

This 8-K filing provides an update on Myriad Genetics' financial performance and condition, which is crucial information for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not appear to contain any immediate, significant negative news.

Key Players & Entities

• MYRIAD GENETICS INC (company) — Registrant
• January 15, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Salt Lake City, Utah (location) — Address of principal executive offices
• 801-584-3600 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Mar

Filing Documents

• mygn-20250115.htm (8-K) — 35KB
• mygnq4pre-announcementatjp.htm (EX-99.1) — 110KB
• 0000899923-25-000002.txt ( ) — 307KB
• mygn-20250115.xsd (EX-101.SCH) — 2KB
• mygn-20250115_def.xml (EX-101.DEF) — 14KB
• mygn-20250115_lab.xml (EX-101.LAB) — 25KB
• mygn-20250115_pre.xml (EX-101.PRE) — 15KB
• mygn-20250115_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

ITEM 2.02 Results of Operations and Financial Condition. On January 15, 2025, Myriad Genetics, Inc. (the "Company") issued a press release announcing its preliminary revenue, loss per share and adjusted earnings per share results for the quarter and full year ended December 31, 2024 and cash and cash equivalents as of December 31, 2024. The Company also introduced full year 2025 financial guidance. The full text of the press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including including the Company's fourth quarter and full year 2024 preliminary revenue, loss per share and adjusted earnings per share and other preliminary financial items as well as the cash and cash equivalents as of December 31, 2024, the Company's full year 2025 financial guidance, and the Company's plan to release actual financial results for the fourth quarter and full year 2024 in February 2025 . These "forward-looking statements" are management's present expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. These risks include, but are not limited to: the risk that sales and profit margins of the Company's existing tests may decline; the risk that the Company may not be able to operate its business on a profitable basis; risks related to changes in the Company's financial results from the preliminary results reported in this Current Report on Form 8-K resulting from the finalization of the Company's financial statements for the fourth quarter and full year ended December 31, 2024 and the audit thereof; risks related to the Company's ability to achieve certain revenue growth targets and generate sufficient revenue from its existing product portfolio or in launching and commercializing new tests to be profitable; risks related to changes in governmental or private insurers' coverage and reimbursement levels for the Company's tests or the Company's ability to obtain reimbursement for its new tests at comparable levels to its existing tests, including with respect to UnitedHealthcare's coverage decisions effective as of first quarter 2025; risks related to increased competition and the development of new c

01 Financial Statements and Exhibits

ITEM 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.9 Press release of Myriad Genetics, Inc., dated January 15, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYRIAD GENETICS, INC. Date: January 15, 2025 By: /s/ Scott J. Leffler Scott J. Leffler Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR